AIM
NVIV

Alambic Investment Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Alambic Investment Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$126K – 615
2016
Q1 		$126K Hold
1
– – 0.04% 436
2015
Q4 		$181K Buy
+1
New +$149K 0.11% 293

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

Alambic Investment Management's NVIV Position: Q2 2016 in Review

Alambic Investment Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2016, closing a stake of 1 share — an estimated $126K sold.

Alambic Investment Management first reported a position in NVIV in Q4 2015 and held it in 2 quarters. The position peaked at $181K in Q4 2015. 44 funds tracked by Wall St. Rank hold NVIV as of Q2 2016.

  • Alambic Investment Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2016 after selling out during the quarter.
  • Alambic Investment Management sold 1 InVivo Therapeutics Holdings Corp share in Q2 2016, an estimated $126K.
  • Alambic Investment Management first reported a position in InVivo Therapeutics Holdings Corp in Q4 2015 and held it in 2 quarters.
  • Alambic Investment Management's InVivo Therapeutics Holdings Corp position peaked at $181K in Q4 2015.
  • 44 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2016.

Based on Alambic Investment Management's 13F filing for Q2 2016, filed 8 Aug 2016.